Dr Karl Peggs

Photo

Personal Profile

Name: Karl Peggs Email: karl.peggs@ucl.ac.uk
Title: Dr Tel:
Department: Research Department of Haematology Fax:
Position: Reader in Haematology Address: , , ,
Research Domain: Personalised Medicine Web Page:  

Profile

Research Description


Research Activities

Gene and Cellular Therapy of Haematological Malignancies

Tumour Immunotherapy

Education Description

UCL Collaborators

Prof Hans Stauss; Prof Adrian Thrasher; Dr Sergio Quezada; Prof Paul Griffiths; Dr Andrew Furness; Prof Samuel Janes; Dr Emma Morris

External Collaborators

Publications

    2014

    • Quezada SA, Peggs KS (2014). An antitumor boost to TH9 cells.. Nat Immunol, 15(8), 703 - 705. doi:10.1038/ni.2945
    • Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C (2014). Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study.. PLoS Biol, 12(7), e1001906 - . doi:10.1371/journal.pbio.1001906
    • Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M (2014). A highly compact epitope-based marker / suicide gene for easier and safer T-cell therapy.. Blood, , - . doi:10.1182/blood-2014-01-545020
    • Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM (2014). Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.. Br J Haematol, , - . doi:10.1111/bjh.12741
    • Chen F, Peniket A, Tholouli E, Bloor A, Chakraverty R, Marks D, Pagliuca A, Russell N, Thomson K, Beard H, Newton K, Raeiszadeh M, Thomas S, Moss P, Peggs KS (2014). CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial.
    • Sellar RS, Peggs KS (2014). Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.. Expert Opin Biol Ther, , - . doi:10.1517/14712598.2014.908847
    • Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE (2014). Immunotherapy: opportunities, risks and future perspectives.. Cytotherapy, 16(4S), S120 - S129. doi:10.1016/j.jcyt.2014.02.001
    • Furness AJ, Vargas FA, Peggs KS, Quezada SA (2014). Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.. Trends Immunol, , - . doi:10.1016/j.it.2014.05.002

    2013

    • Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, Ardeshna K, Linch DC, Peggs KS (2013). Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.. Br J Haematol, , - . doi:10.1111/bjh.12582
    • Peggs KS (2013). Attack of the T-cell clones.. Blood, 122(11), 1847 - 1848. doi:10.1182/blood-2013-07-511022
    • Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S (2013). EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.. Bone Marrow Transplant, , - . doi:10.1038/bmt.2013.170
    • Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C (2013). Ultra-deep T-cell receptor sequencing reveals the complexity and intratumour heterogeneity of T-cell clones in renal cell carcinomas.. J Pathol, , - . doi:10.1002/path.4284
    • Oxenham T, Southern P, Briesemeister D, Freeman A, Peggs K, Pankhurst Q, Quezada S, Chester K (2013). Development of Hyperthermia Treatments for Malignant Melanoma using Superparamagnetic Iron Oxide Nanoparticles in a Novel Transgenic In Vivo Model.
    • Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.. J Exp Med, , - . doi:10.1084/jem.20130579
    • Townsend WM, Holroyd A, Pearce R, Mackinnon S, Naik P, Goldstone AH, Linch DC, Peggs KS, Thomson KJ, Singer M, Howell DC, Morris EC (2013). Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.. Br J Haematol, 161(4), 578 - 586. doi:10.1111/bjh.12294
    • Thomson KJ, Kayani I, Ardeshna K, Morris EC, Hough R, Virchis A, Goldstone AH, Linch DC, Peggs KS (2013). A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia, 27(6), 1419 - 1422. doi:10.1038/leu.2012.318
    • Newton K, Skulte A, Mitra A, Hodgkin K, Peggs KS, Friedetzky A, Knaus F (2013). Centralized production and distribution of CMV-specific cytotoxic T cell lymphocytes ready for commercialization.
    • Jamal-Hanjani M, Thanopoulou E, Peggs KS, Quezada SA, Swanton C (2013). Tumour heterogeneity and immune-modulation.. Curr Opin Pharmacol, 13(4), 497 - 503. doi:10.1016/j.coph.2013.04.006
    • Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A, British Committee for Standards in Haematology , British Society of Blood and Marrow Transplantation , UK Virology Network (2013). Management of cytomegalovirus infection in haemopoietic stem cell transplantation.. Br J Haematol, 162(1), 25 - 39. doi:10.1111/bjh.12363
    • Quezada SA, Peggs KS (2013). Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.. Br J Cancer, 108(8), 1560 - 1565. doi:10.1038/bjc.2013.117
    • Thomson KJ, Peggs KS (2013). Allogeneic transplantation in the UK: an aggregation of marginal gains?. Br J Haematol, , - . doi:10.1111/bjh.12497

    2012

    • Hockings C, Peggs K (2012). Life after allogeneic bone marrow transplant.. Br J Hosp Med (Lond), 73(6), C93 - C96.
    • Direkze S, Mansour M, Rodriguez-Justo M, Kibbler C, Gant V, Peggs KS (2012). Candida kefyr fungal enteritis following autologous BMT.. Bone Marrow Transplant, 47(3), 465 - 466. doi:10.1038/bmt.2011.112
    • Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, Peggs K, Statham P, Goldstone AH (2012). Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience.. Leuk Lymphoma, 53(12), 2397 - 2404. doi:10.3109/10428194.2012.694430
    • Nicholson E, Mackinnon S, Thomson KJ, Sudak J, Fielding AK, Kottaridis P, Peggs KS, Morris EC, Chakraverty R (2012). FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION.
    • Sellar RS, Peggs KS (2012). Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.. Future Oncol, 8(12), 1549 - 1565. doi:10.2217/fon.12.153
    • Peggs KS, Quezada SA (2012). PD-1 blockade: promoting endogenous anti-tumor immunity.. Expert Rev Anticancer Ther, 12(10), 1279 - 1282. doi:10.1586/era.12.109
    • Sive JI, Thomson KJ, Morris EC, Ward KN, Peggs KS (2012). Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.. Clin Infect Dis, 55(10), 1362 - 1370. doi:10.1093/cid/cis689
    • Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, Linch DC, Ardeshna K (2012). Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.. Br J Haematol, 157(5), 543 - 552. doi:10.1111/j.1365-2141.2012.09096.x
    • Sellar RS, Ward KN, Thomson KJ, Peggs KS (2012). Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT.. Bone Marrow Transplant, 47(11), 1482 - 1483. doi:10.1038/bmt.2012.46
    • Sellar RS, Peggs KS (2012). The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation.. Cytotherapy, 14(4), 391 - 400. doi:10.3109/14653249.2012.662769
    • Thomson KJ, Kottaridis P, Cassoni A, Morris EC, Khwaja A, Linch DC, Chakraverty R, Peggs KS, Mackinnon S (2012). ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZUMAB-DEPLETED GRAFTS.
    • Thomson KJ, Mackinnon S, Peggs KS (2012). CMV-specific cellular therapy for acute myeloid leukemia?. Blood, 119(4), 1088 - 1090. doi:10.1182/blood-2011-10-383943
    • Moore S, Peggs K, Thomson K, Lowry L, Ljubic A, Goldstone AH, Linch DC, Ardeshna KM (2012). Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. BRITISH JOURNAL OF HAEMATOLOGY, 156(1), 142 - 144. doi:10.1111/j.1365-2141.2011.08818.x
    • Sellar RS, Peggs KS (2012). Management of multidrug-resistant viruses in the immunocompromised host.. Br J Haematol, 156(5), 559 - 572. doi:10.1111/j.1365-2141.2011.08988.x
    • Mohamedbhai SG, Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS (2012). Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.. Br J Haematol, 156(4), 516 - 522. doi:10.1111/j.1365-2141.2011.08944.x
    • Sellar RS, Peggs KS (2012). Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.. Expert Opin Biol Ther, 12(9), 1161 - 1172. doi:10.1517/14712598.2012.693471

    2011

    • Townsend W, Holroyd A, Pearce RM, Mackinnon S, Goldstone AH, Linch DC, Peggs KS, Thomson K, Singer M, Naik P, Howell D, Morris E (2011). A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically III Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning.
    • Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, Pang K, Mackinnon S, Lowdell MW (2011). Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.. Clin Infect Dis, 52(1), 49 - 57. doi:10.1093/cid/ciq042
    • Quezada SA, Peggs KS (2011). Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities.. Immunotherapy, 3(8), 915 - 917. doi:10.2217/imt.11.83
    • Moore S, Peggs K, Thomson K, Ljubic A, Goldstone AH, Linch DC, Ardeshna K (2011). AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY.
    • Robinson SP, Luan J, Canals C, Peggs K, Le Gouill S, Nicolaus K, Milpied N, Jouet J, Briones J, Guilhot F, Finke J, Sureda A, Schmitz N (2011). REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE.
    • Richardson S, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding A, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs K, Thomson K, Vandenberghe E, Mackinnon S, Chakraverty R (2011). Risk-stratified adoptive cellular therapy following allogeneic haematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Jouurnal of Haematology, In press, - .
    • Peggs KS, Kayani I, Thomson K, Morris E, Kottaridis P, Ardeshna KM, Fielding A, Hough R, Goldstone AH, Chakraverty R, Linch DC, Mackinnon S (2011). Positive Pre-Transplantation ([18-F]) FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma.
    • Kothari J, Ljubic A, Peggs KS, Thomson K, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM (2011). Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure.
    • Peggs K (2011). The role of alemtuzumab in allogeneic stem cell transplantation.
    • Raj D, Peggs K, Pule M, Linch D, Davies M, Nathwani A (2011). Adoptive immunotherapy for patients with chronic lymphocytic leukaemia using a chimeric antigen receptor targeting CD23.
    • Peggs KS (2011). Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies.. Expert Rev Anticancer Ther, 11(11), 1667 - 1670. doi:10.1586/era.11.159
    • Quezada SA, Peggs KS, Simpson TR, Allison JP (2011). Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.. Immunol Rev, 241(1), 104 - 118. doi:10.1111/j.1600-065X.2011.01007.x
    • Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S (2011). Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.. J Clin Oncol, 29(8), 971 - 978. doi:10.1200/JCO.2010.32.1711
    • Roddie C, Peggs KS (2011). Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.. Expert Opin Biol Ther, 11(4), 473 - 487. doi:10.1517/14712598.2011.554811
    • Thomson K, Kayani I, Ardeshna KM, Morris E, Hough R, Goldstone AH, Linch DC, Peggs KS (2011). Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma.

    2010

    • Mead A, Thomson KJ, Morris EC, Mohamedbhai S, Orti G, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2010). HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning.
    • Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S (2010). Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.. Blood, 115(14), 2763 - 2768. doi:10.1182/blood-2009-11-255182
    • Peggs KS, Quezada SA (2010). Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.. Expert Rev Anticancer Ther, 10(11), 1697 - 1701. doi:10.1586/era.10.144
    • Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K (2010). NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biol Blood Marrow Transplant, 16(11), 1467 - 1503. doi:10.1016/j.bbmt.2010.08.001
    • Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S (2010). T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.. J Clin Oncol, 28(23), 3695 - 3700. doi:10.1200/JCO.2009.26.9100
    • Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080 - 3088. doi:10.1182/blood-2010-05-286856
    • Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP (2010). Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.. J Exp Med, 207(3), 637 - 650. doi:10.1084/jem.20091918
    • Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2010). HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.. Blood, 115(25), 5147 - 5153. doi:10.1182/blood-2010-01-265413
    • Peggs KS, Thomson K, Morris E, Kottaridis P, Hough R, Goldstone A, Fielding A, Ardeshna K, Chakraverty R, Linch DC, Mackinnon S (2010). Donor lymphocyte infusions guided by PET-CT offer durable salvage in relapsed Hodgkin's lymphoma post-allogeneic transplantation.
    • Orti G, Peggs K, Collin M, Clark R, Milligan D, Roddie H, Liakopoulou E, Crawley C, Clark A, Pettengel R, Chowdhry N, Roughton M, Snowden J, Morris E, Thomson K, Kottaridis P, Fielding A, Mackinnon S, Chakraverty R, UK Collaborative Grp (2010). Final results of UK multi-centre, phase II study of Campath-1h dose de-escalation prior to non-myeloablative hla-identical sibling stem cell transplantation.
    • Thomson K, Morris E, Milligan D, Parker A, Hunter A, Cook G, Bloor A, Clark F, Kazmi M, Linch D, Chakraverty R, Peggs K, Mackinnon S (2010). T-cell depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
    • Richardson S, Vandenberghe E, Benjamin R, Sudak J, Goldstone A, Thomson K, Morris E, Peggs K, Fielding A, Kottaridis P, MacKinnon S, Chakraverty R (2010). Reduced-intensity allografting with in vivo T-cell depletion is associated with a favourable outcome in chronic lymphocytic leukaemia.
    • Mackinnon S, Lambert J, Bomanji J, Peggs K, Thomson K, Chakraverty R, Fielding A, Kottaridis P, Roughton M, Morris E, Goldstone A, Linch D, Ell P (2010). Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplant for lymphoma.
    • Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N (2010). Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.. Haematologica, 95(6), 989 - 995. doi:10.3324/haematol.2009.013920

    2009

    • Peggs KS, Thomson K, Morris E, Chowdhry N, Verfuerth S, Kottaridis P, Goldstone AH, Ardeshna K, Linch D, Chakraverty R, Mackinnon S (2009). Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.
    • Peggs KS, Krauss A, Mackall C (2009). Clinical implications of immune reconstitution following autologous and allogeneic transplantation.. In Bishop MR (Ed.), Hematopoietic Stem Cell Transplantation (pp. 131 - 154). : Springer Verlag.
    • Thomson K, Kottaridis P, Morris E, Chakraverty R, Peggs K, Mackinnon S (2009). Successful myeloablative transplantation in high-risk acute myeloid leukaemia using unrelated donors with alemtuzumab for T-cell depletion.
    • Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty R, Peggs KS, Mackinnon S (2009). Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.. J Clin Oncol, 27(3), 426 - 432. doi:10.1200/JCO.2008.17.3328
    • Roddie C, Paul J, Benjamin R, Gallimore CI, Xerry J, Gray JJ, Peggs KS M, E T, KJ W, KN (2009). Allogeneic haematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognised cause of morbidity.. Clinical Infectious Diseases, 49(7), 1061 - 1068.
    • Holroyd A, Townsend W, Naik P, Mackinnon S, Howell D, Goldstone A, Linch D, Peggs K, Thomson K, Singer M, Morris E (2009). Favourable outcome for allogeneic haematopoietic transplant recipients requiring intensive therapy unit admission with improved survival following reduced intensity conditioning.
    • Orti G, Fielding A, Kottaridis P, Morris E, Thomson K, Lowdell M, Peggs K, Mackinnon S, Chakraverty R (2009). Phase I study of high-stringency CD8-depletion of donor leukocyte transfusions following allogeneic haematopoietic stem cell transplantation.. Transplantation, 88, 1312 - 1318.
    • Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S (2009). Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.. Clin Infect Dis, 49(12), 1851 - 1860. doi:10.1086/648422
    • Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Pang K, Chakraverty R, Mackinnon S, Lowdell MW (2009). Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.
    • Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A, Center for International Blood and Marrow Transplant Research (CIBMTR) , National Marrow Donor Program (NMDP) , European Blood and Marrow Transplant Group (EBMT) , American Society of Blood and Marrow Transplantation (ASBMT) , Canadian Blood and Marrow Transplant Group (CBMTG) , Infectious Disease Society of America (IDSA) , Society for Healthcare Epidemiology of America (SHEA) , Association of Medical Microbiology and Infectious Diseases Canada (AMMI) , Centers for Disease Control and Prevention (CDC) (2009). Background to hematopoietic cell transplantation, including post transplant immune recovery.. Bone Marrow Transplant, 44(8), 457 - 462. doi:10.1038/bmt.2009.255
    • Peggs KS, Quezada SA, Sharma P, Allison JP (2009). Cancer immunotherapy. In Hong WK, Bast RC, Hait W, Kufe DW, Pollock RE, Holland JF, Weichselbaum RR (Ed.), Cancer medicine 8 (pp. 175 - 189). : Pmph USA Ltd.
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.. J Exp Med, 206(8), 1717 - 1725. doi:10.1084/jem.20082492
    • Townsend W, Cross NC, Waghorn K, Somana K, Ramsay A, Thomson K, Peggs K (2009). Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder.. Bone Marrow Transplant, 44(3), 197 - 199. doi:10.1038/bmt.2008.448
    • Peggs KS, Quezada SA, Allison JP (2009). Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.. Clin Exp Immunol, 157(1), 9 - 19. doi:10.1111/j.1365-2249.2009.03912.x
    • Peggs KS (2009). Adoptive T cell immunotherapy for cytomegalovirus.. Expert Opin Biol Ther, 9(6), 725 - 736. doi:10.1517/14712590902967588
    • Roddie C, Peggs K (2009). Hodgkin’s Lymphoma. Medicine, 37(4), 208 - 211.
    • Roddie C, Paul J, Benjamin R, Gallimore C, Xerry J, Gray JJ, Peggs K, Morris E, Thomson K, Ward K (2009). Allogeneic haematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognised cause of morbidity.
    • Peggs KS, Krauss AC, Mackall CL (2009). Clinical implications of immune reconstitution following hematopoietic stem cell transplantation.. Cancer Treat Res, 144, 131 - 154. doi:10.1007/978-0-387-78580-6_6
    • Holroyd A, Townsend W, Naik P, Mackinnon S, Howell D, Goldstone A, Linch D, Peggs K, Thomson K, Singer M, Morris E (2009). Favourable outcome for haematopoietic transplant recipients requiring intensive therapy unit admission: a 10-year single-centre experience.

    2008

    • Orti G, Peggs K, Thomson K, Morris E, Lowdell M, Mackinnon S, Chakraverty R (2008). Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogencic Stem Cell Transplantation..
    • Bloor AJ, Thomson KJ, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2008). High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 14(1), 50 - 58.
    • Kottaridis PD, Thomson K, Fielding AK, Morris E, Chakraverty R, Peggs K, Mackinnon S (2008). Successful salvage of high risk/relapsed AML with T-cell depleted allogeneic transplant: comparable outcome to standard risk disease even with the use of unrelated donors.
    • Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP (2008). Epitope landscape in breast and colorectal cancer.. Cancer Res, 68(3), 889 - 892. doi:10.1158/0008-5472.CAN-07-3095
    • Mead AJ, Thomson KJ, Morris EC, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2008). Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation.
    • Peggs KS, Verfuerth S, Pizzey A, Chow C, Thomson K, Mackinnon S (2008). CMV-Specific T cell Immunotherapy Promotes Restoration of Durable Functional Immunity in High Risk Patients Following Allogeneic Stem Cell Transplantation.
    • Robinson SP, Sureda A, Canals C, Vernant JP, Milpied NJ, Finke J, Maertens J, Jouet JP, Craddock CF, Peggs KS, Le Gouill S, Schmitz N (2008). Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT.
    • Lambert JR, Bomanji JB, Cooper N, Hart DP, Peggs K, Thomson K, Ell PJ, Mackinnon S (2008). Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy.
    • Peggs KS, Anderlini P, Sureda A (2008). Allogeneic transplantation for Hodgkin lymphoma.. Br J Haematol, 143(4), 468 - 480. doi:10.1111/j.1365-2141.2008.07349.x
    • Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP (2008). Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.. J Exp Med, 205(9), 2125 - 2138. doi:10.1084/jem.20080099
    • Peggs KS, Quezada SA, Allison JP (2008). Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.. Immunol Rev, 224, 141 - 165. doi:10.1111/j.1600-065X.2008.00649.x
    • Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2008). Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. BONE MARROW TRANSPL, 41(9), 765 - 770. doi:10.1038/sj.bmt.1705977
    • Mackinnon S, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Linch DC, Chakraverty RK, Peggs KS, Thomson KJ (2008). Excellent long-term survival following reduced intensity allogeneic transplantation for multiply relapsed follicular lymphoma.
    • Mackinnon S, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Linch DC, Chakraverty RK, Peggs KS, Thomson KJ (2008). Favourable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins lymphoma.
    • Kottaridis P, Thomson K, Cassoni A, Pearce R, Chakraverty R, Morris E, Peggs K, Mackinnon S (2008). Myeloablative allogeneic stem cell transplantation with unrelated donors for high-risk acute myeloid leukaemia: no increase in relapse with alemtuzumab-depleted grafts.
    • Shaw B, Russell N, Pagliuca A, Apperley J, Cook G, Mackinnon S, Madrigal J, Marks D, Morgan G, Pearce R, Peggs K, Potter M, Towlson K, Byrne J, Study ANT & BSBMT (2008). No impact on survival is seen when comparing the use of BM or PBSC as the stem cell source in recipients of T-cell depleted myeloablative transplants for leukaemia and MDS.
    • Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A PR, Milligan D MEC, Goldstone AH LDC, Mackinnon S (2008). Superiority of reduced intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation.. Bone Marrow Transplantation, 41(9), 765 - 770.
    • Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S (2008). The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.. Biology of Blood and Marrow Transplantation, 14(11), 1288 - 1297.
    • Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M (2008). Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.. Blood Cells Mol Dis, 40(1), 63 - 67. doi:10.1016/j.bcmd.2007.07.003
    • Verfuerth S, Peggs KS, Pizzey A, Chowdhry N, Mackinnon S (2008). Cytomegalovirus (CMV)-Specific CD8+T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active..

    2007

    • Peggs KS, Quezada SA, Simpson TR, Allison JP (2007). Dissociation of systemic and local anti-tumor immunity following depletion of regulatory T cells limits therapeutic activity in established tumors.
    • Thomson K, Morris E, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Chakraverty R, Peggs K, Mackinnon S (2007). Long-term follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for aggressive non-Hodgkins lymphoma.
    • Peggs KS, Quezada SA, Allison JP (2007). Checkpoint blockade and combinatorial immunotherapies.. In Kaufman HL, Wolchok JD (Ed.), General principles of tumor immunotherapy (pp. 363 - 390). : Springer Verlag.
    • Thomson K, Morris E, Milligan D, Hunter A, Cook G, Bloor A, Craddock C, Yung L, Parker A, Chakraverty R, Peggs K, Mackinnon S (2007). Extended follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for follicular lymphoma.
    • Chakraverty R, Manji N, Clark R, Crawley C, Johnson P, Liakopoulou E, Marsh J, Milligan D, Morris E, Peggs K, Thomson K, Snowden J, Jackson G, Mackinnon S (2007). Multi-center phase II study of CAMPATH-1H dose de-escalation prior to nonmyeloablative HLA-identical sibling transplantation.
    • Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Miguel JS, Peggs K, Sierra J, Milligan D, Mackinnon S (2007). The effect of in vivo T-cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    • Thomson KJ, Mackinnon S, Peggs KS (2007). T-cell depleted haematopoietic stem cell transplantation and salvage donor lymphocyte infusions. In Davenport LP (Ed.), Stem cell research advances (pp. 111 - 136). : Nova Biomedical.
    • Mackinnon S, Thomson KJ, Goldstone AH, Linch DC, Peggs KS (2007). Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation.
    • Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S, UK Spanish Collaborative Grps (2007). Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. BRIT J HAEMATOL, 139(1), 70 - 80. doi:10.1111/j.1365-2141.2007.06759.x
    • Hart DP, Peggs KS (2007). Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies.. Clin Pharmacol Ther, 82(3), 325 - 329. doi:10.1038/sj.clpt.6100283
    • Peggs KS, Segal NH, Allison JP (2007). Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.. Cancer Cell, 12(3), 192 - 199. doi:10.1016/j.ccr.2007.08.023
    • Thomson KJ, Peggs KS, Blundell E, Goldstone AH, Linch DC (2007). A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.. Leuk Lymphoma, 48(5), 881 - 884. doi:10.1080/10428190701216394
    • Bloor A, Thomson K, Chowdury N, Verfeuth S, Ings S, Chakraverty R, Goldstone A, Linch D, Peggs KAM, S (2007). High response rate to donor lymphocyte infusion (DLI) following allogeneic stem cell transplanatation for indolent non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation, , - .
    • Shaw BE, Russell NH, Pagliuca A, Apperley J, Cook G, Mackinnon S, Madrigal JA, Marks D, Morgan GJ, Peggs K, Potter MN, Towlson K, Byrne JL (2007). A comparison of stem cell source in recipients of T-Cell depleted myeloablative transplants for leukaemia: No difference in mortality using BM or PBSC.

    2006

    • Thomson KJ, Mackinnon S, Peggs KS (2006). T-cell depleted allogeneic haematopoietic stem cell transplantation and salvage donor lymphocyte infusions: a viable option in the era of reduced intensity transplantation?. In Davidson DF (Ed.), Bone marrow transplantation (pp. 57 - 82). : Nova Biomedical.
    • Peggs KS (2006). Improving cellular therapies in Epstein - Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulators.. Leuk Lymphoma, 47(5), 787 - 789. doi:10.1080/10428190600648630
    • Chantry AD, Snowden JA, Craddock C, Peggs K, Roddie C, Craig JI, Orchard K, Towlson KE, Pearce RM, Marks DI, BSBMT Clinical Trials Committee (2006). Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.. Biol Blood Marrow Transplant, 12(12), 1310 - 1317. doi:10.1016/j.bbmt.2006.07.015
    • Chakraverty R, Dimopoulou M, Glanville J, Thomson K, Peggs K, Milligan D, Cook G, Jackson G, Parker A, Hunter A, Russell N, Pearce R, Mackinnon S (2006). De-escalation of the alemtuzumab dose prior to nonmyeloablative HLA-identical sibling transplantation: Crucial role of timing..
    • Delgado J, Cooper N, Thomson K, Duarte R, Jarmulowicz M, Cassoni A, Kortaridis P, Peggs K, Mackinnon S (2006). The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation. BIOL BLOOD MARROW TR, 12(1), 75 - 83. doi:10.1016/j.bbmt.2005.08.036
    • Peggs KS, Quezada SA, Korman AJ, Allison JP (2006). Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.. Curr Opin Immunol, 18(2), 206 - 213. doi:10.1016/j.coi.2006.01.011
    • Moran J, Verfuerth S, Peggs K, Mackinnon S (2006). Impact of CMV-specific immunotherapy on duration and cost of anti-viral therapy.
    • Korman AJ, Peggs KS, Allison JP (2006). Checkpoint blockade in cancer immunotherapy.. Adv Immunol, 90, 297 - 339. doi:10.1016/S0065-2776(06)90008-X
    • Peggs KS (2006). Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans.. Cytotherapy, 8(5), 427 - 436. doi:10.1080/14653240600851938
    • Quezada SA, Peggs KS, Curran MA, Allison JP (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.. Journal of Clinical Investigation, 116(7), 1935 - 1945. doi:10.1172/JCI27745

    2005

    • Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer H, Ayuk F, Zander A, Marks D (2005). Comparison between anti-thymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch in melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated SCT in patients with multiple myeloma.
    • Peggs KS, Mackinnon S, Linch DC (2005). The role of allogeneic transplantation in non-Hodgkin's lymphoma.. British Journal of Haematology, 128(2), 153 - 168.
    • Thomson KJ, Peggs KS, Morris EC, Khwaja A, Linch DC, Goldstone AH, Mackinnon S (2005). Allogeneic stem cell transplantation with T cell depletion for acute myeloid leukaemia.
    • Thomson KJ, Peggs KS, Morris EC, Khwaja A, Linch DC, Goldstone AH, Mackinnon S (2005). Allogeneic stem cell transplantation for high-risk acute myeloid leukemia: No increase in relapse with alemtuzumab-depleted grafts..
    • Tauro S, Mackinnon S, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Craddock C (2005). Allogeneic stem cell transplantation using a reduced intensity conditioning (RIC) regimen has the capacity to produce durable remissions and long term disease-free survival in patients with high risk acute myeloid leukemia (AML)..
    • Bloor AJC, Thomson K, Cooper N, Peggs KS, Mackinnon S (2005). Dose-escalated donor lymphocyte infusions post allogeneic transplantation in non-Hodgkin's lymphoma.
    • Peggs KS, Allison JP (2005). Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily.. Br J Haematol, 130(6), 809 - 824. doi:10.1111/j.1365-2141.2005.05627.x
    • Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Morris E, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S (2005). Clinical evidence of a graft versus Hodgkin's Lymphoma effect following reduced intensity allogeneic transplantation.. The Lancet, 365(9475), 1934 - 1941. doi:10.1016/S0140-6736(05)66659-7
    • Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S (2005). The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.. Bone Marrow Transplant, 35(11), 1065 - 1069. doi:10.1038/sj.bmt.1704959
    • Laurence AD, Peggs KS (2005). Cerebral and pulmonary nocardia in a bone marrow transplant patient.. Br J Haematol, 129(6), 711 - . doi:10.1111/j.1365-2141.2005.05474.x
    • Thomson KJ, Peggs KS (2005). Role of allogeneic stem cell transplantation in multiple myeloma.. Expert Rev Anticancer Ther, 5(3), 455 - 464. doi:10.1586/14737140.5.3.455
    • Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Bjorkstrand B, Niederwieser D, Gahrton G, Apperley JF, Chronic Leukaemia Working Party EB (2005). Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. BLOOD, 105(11), 4532 - 4539. doi:10.1182/blood-2004-06-2387
    • Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group (2005). Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.. Br J Haematol, 129(5), 631 - 643. doi:10.1111/j.1365-2141.2005.05513.x
    • Mansour MR, Dogan A, Morris EC, Khwaja A, Linch DC, Mackinnon S, Peggs KS (2005). Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.. Bone Marrow Transplant, 35(9), 931 - 934. doi:10.1038/sj.bmt.1704897
    • Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S (2005). Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.. Journal of Clinical Oncology, 23(36), 9387 - 9393.
    • Thomson KJ, Morris EC, Milligan D, Cook G, Cavet J, Craddock C, Hunter A, Schey S, Parker A, Goldstone AH, Linch DC, Peggs KS, Mackinnon S (2005). Reduced intensity allogeneic transplantation for non-Hodgkin's Lymphoma: Extended follow-up of an alemtuzumab-containing regimen..
    • Thomson KJ, Peggs KS, Sureda A, Hunter A, Caballero MD, Cavet J, Urbano-Ispizua A, Parker A, Ribera JM, Mahendra P, Milligan D, Morris EC, Goldstone AH, Linch DC, Sierra J, Mackinnon S (2005). Impact of in vivo T cell depletion on outcome following reduced intensity transplantation with matched related donors for Hodgkin lymphoma: comparison between two prospective studies.
    • Thomson KJ, Peggs KS, Smith P, Chopra R, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2005). Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation..
    • Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Mackinnon S (2005). Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.. Br J Haematol, 128(6), 824 - 829. doi:10.1111/j.1365-2141.2005.05388.x
    • Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT) (2005). Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.. Br J Haematol, 128(4), 496 - 502. doi:10.1111/j.1365-2141.2004.05330.x
    • Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL (2005). Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.. Clinical Cancer Research, 11, 3377 - 3384. doi:10.1158/1078-0432.CCR-04-0650
    • Jalal H, Bibby DF, Tang JW, Bennett J, Kyriakou C, Peggs K, Cubitt D, Brink NS, Ward KN, Tedder RS (2005). First reported outbreak of diarrhea due to adenovirus infection in a hematology unit for adults. Journal of Clinical Microbiology, 43(6), 2575 - 2580.
    • Peggs KS (2005). The role of alemtuzumab in allogeneic stem cell transplantation. In Hillmen P, Witzig TE (Ed.), Therapeutic Strategies in Lymphoid Malignancy (pp. 177 - 188). : Informa HealthCare.

    2004

    • Peggs KS, Sureda A, Hunter A, Caballero MD, Cavet J, Urbano-Ispizua A, Parker A, Ribera JM, Mahendra P, Canales MA, Milligan D, Hernandez-Boluda JC, Morris HBC, Alvarez I, Goldstone AH, Linch DC, Sierra J, Mackinnon S (2004). Impact of in vivo T-cell depletion on outcome following reduced intensity transplantation for Hodgkin lymphoma: Comparison between 2 prospective studies.
    • Cooper N, Avivi I, Peggs K, Hart D, Thomson K, Goldstone A, Linch D, Ell P, Bomanji J, Mackinnon S (2004). The role of PET scanning in directing immune manipulations following reduced intensity transplants in adults with lymphoid malignancies..
    • Peggs KS, Verfuerth S, Pizzy A, Khan N, Guiver M, Moss PA, Mackinnon S (2004). Adoptive cellular therapy for early cytomegalovirus infection following allogeneic stem cell transplantation using virus- specific T-cell lines. Blood Cells, Molecules, and Diseases, 33(3), 198 - 199.
    • Peggs K, Mackinnon S (2004). Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?. LEUKEMIA, 18(9), 1541 - 1542. doi:10.1038/sj.leu.2403432
    • Delgado J, Cooper N, Thomson K, Duarte R, Kottaridis P, Peggs K, Mackinnon S (2004). The importance of age, fludarabine and total body irradiation in the incidence and severity of chronic renal failure following allogeneic hematopoietic stem cell transplantation..
    • Peggs KS, Verfuerth S, Chow C, Thomson K, Goldstone AH, Linch DC, Mackinnon S (2004). Adoptive cellular therapy for cytomegalovirus following allogeneic stem cell transplantation: Toxicity and efficacy.
    • Peggs KS, Mackinnon S (2004). Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation.. The International Journal of Biochemistry and Cell Biology, 36(4), 695 - 701.
    • Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. BLOOD, 104(13), 3865 - 3871. doi:10.1182/blood-2004-03-1105
    • Kroeger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Schwerdtfeger R, Kiehl M, Sayer HG, Ayuk F, Eiermann T, Marks D (2004). Comparison between anti-thymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch in melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated stem cell transplantation in patients with multiple myeloma..
    • Peggs K (2004). Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2(4), 559 - 573.
    • D'Sa S, Yong K, Kyriakou C, Bhattacharya S, Peggs KS, Foulkes B, Watts MJ, Ings SJ, Ardeshna KM, Goldstone AH, Williams CD (2004). Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.. Br J Haematol, 125(6), 756 - 765. doi:10.1111/j.1365-2141.2004.04981.x
    • Peggs KS (2004). Immune reconstitution following stem cell transplantation.. Leuk Lymphoma, 45(6), 1093 - 1101.
    • Peggs KS, Thomson K, Hunter A, Chopra R, Mahendra P, Milligan D, Parker A, Pettengell R, Craddock C, Hale G, Waldmann H, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2004). Exploiting alloreactivity in relapsed and refractory Hodgkin Lymphoma: long-term follow-up of a T-cell-depleted reduced intensity transplant protocol.
    • Hart DP, Thomson KJ, Bannerjee L, Morris EC, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2004). Very low dose aciclovir prophylaxis postallogeneic stem cell transplantation prevents varicella zoster infection without development of clinically relevant resistance.
    • Tauro S, Craddock C, Peggs K, Begum G, Chopra R, Littlewood T, Parker A, Marsh J, Cook G, Hale G, Snowden J, Milligan D, Hunter A, Russell N, Goldstone A, Mahendra P, Linch D, Mackinnon S (2004). Outcome of allogeneic stem cell transplantation in adults with high-risk myeloid malignancies using an alemtuzemab based reduced-intensity-conditioning regimen.
    • Morris E, Thomson K, Craddock C, Milligan D, Smith G, Parker A, Schey S, Winfield D, Chopra R, Littlewood T, Tighe J, Hunter A, Kyriakou C, Kottaridis P, Linch D, Goldstone A, Peggs K, Mackinnon S (2004). Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
    • Kroger N, Thomson K, Zabelina T, Peggs K, Chopra R, Shimoni A, Nagler A, Milligan D, Craddock C, Parker A, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Chakraverty R, Beyer J, Ayuk F, Zander A, Mackinnon S, United Kingdom Collaborative Grp N , German Cooperative Transplant Grp (2004). Comparison between anti-thymocyte globulin and alemtuzumab as part of the melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated stem cell transplantation in patients with lymphoid malignancies.
    • Thomson KJ, Ings S, Watts M, Mackinnon S, Peggs KS (2004). CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion.. Blood, 103(2), 743 - . doi:10.1182/blood-2003-08-2896
    • Peggs KS, Mackinnon S (2004). Immune reconstitution following haematopoietic stem cell transplantation. BR J HAEMATOL, 124 Feb 2004(4), 407 - 420.
    • Peggs KS (2004). Role of MabCampath in allogeneic transplantation. ANNALS OF HEMATOLOGY, 83(Suppl 1), S66 - S68.
    • Peggs KS, Thomson K, Hart DL, Geary J, Morris E, Yong K, Goldstone A, Linch D, Mackinnon S (2004). Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103(4), 1548 - 1556. doi:10.1182/blood-2003-05-1513
    • Peggs K, Mackinnon S, Ayuk FA, Zander AR, Kröger N (2004). Graft-versus-myeloma: Are durable responses a clinical reality following donor lymphocyte infusion? (multiple letters) (2). Leukemia, 18(9), 1541 - 1543.
    • Peggs K (2004). Imatinib mesylate - gold standards and silver linings. CLINICAL AND EXPERIMENTAL MEDICINE, 4(1), 1 - 9.
    • Peggs KS, Mackinnon S (2004). Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-Cell therapy. HUMAN IMMUNOLOGY, 65(5), 550 - 557.
    • Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS (2004). Reduced intensity transplantation: where are we now?. Hematol J, 5 Suppl 3, S34 - S38. doi:10.1038/sj.thj.6200419

    2003

    • Thomson K, Hart D, Cook G, Milligan D, Parker A, Marsh J, Chopra R, Littlewood T, Linch D, Goldstone A, Morris E, Hale G, Peggs K, Mackinnon S (2003). Lowering the dose of in vivo alemtuzumab (Campath-1H) in reduced intensity conditioning for allogeneic transplantation results in more graft-versus-host disease..
    • Rew SB, Lopes L, Koishihara Y, Kosaka M, Ozaki S, Peggs K, Chain B, Yong KL (2003). Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HMI.24..
    • Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriacou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K (2003). Reduced intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-senstive myeloma: limited efficacy of graft-versus-tumor activity.. Biology of Blood and Marrow Transplantation, 9(4), 257 - 265. doi:10.1053/bbmt.2003.50009
    • Kyriakou CA, D'Sa SP, Flory A, Hanslip J, Peggs KS, Yong KL (2003). Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma.
    • Hunter HM, Peggs K, Powles R, Apperley J, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams C, Cook G, Towlson K, Marks D, Russell NH (2003). A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma.
    • Shaw BE, Peggs K, Bird JM, Cavenaugh J, Hunter A, Madrigal JA, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI (2003). The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British Journal of Haematology, 123, 886 - 895.
    • PEGGS KS, MACKINNON S (2003). Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia. New England Journal of Medicine, 348(11), 1048 - 1050.
    • PEGGS KS, Verfuerth S, D'Sa S, Yong K, MACKINNON S (2003). Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. British Journal of Haematology, 120, 154 - 165.
    • PEGGS KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, MACKINNON S (2003). Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. The Lancet, 362(9393), 1375 - 1377. doi:10.1016/S0140-6736(03)14634-X
    • Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone AH, Yong K, Mackinnon S (2003). Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection.. Biol Blood Marrow Transplant, 9(3), 198 - 205. doi:10.1053/bbmt.2003.50010
    • Peggs KS, Banerjee L, Thomson K, Mackinnon S (2003). Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion.. Bone Marrow Transplant, 31(8), 725 - 726.
    • Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G (2003). Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.. Blood, 102(1), 404 - 406. doi:10.1182/blood-2002-09-2687
    • D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K (2003). T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.. Br J Haematol, 123(2), 309 - 322.
    • Hunter HM, Peggs K, Powles R, Apperley J, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams C, Cook G, Towlson K, Marks D, Russell NH (2003). A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma..
    • Kyriakou CA, D'Sa SP, Flory A, Hanslip J, Peggs KS, Yong KL (2003). Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma..
    • Duarte RF, Morris EC, Shaw BE, Thomson KJ, Ethell M, Peggs KS, Potter MN, Mackinnon S (2003). Recipient CMV seropositivity may adversely affect the outcome of unrelated donor transplantation by increasing the risk of disease relapse..
    • Kroger N, Thomson K, Zabelina T, Peggs K, Chopra R, Shimoni A, Nagler A, Milligan DW, Craddock C, Parker A, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Chakraverty R, Beyer J, Ayuk F, Zander A, Mackinnon S (2003). Comparison between anti-thymocyte globulin and alemtuzumab in melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated stem cell transplantation in patients with lymphoid malignancies..
    • Hart DP, Thomson KJ, Bannerjee L, Morris EC, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2003). Very low dose aciclovir prophylaxis post allogeneic stem cell transplantation prevents varicella zoster infection without development of clinically relevant resistance..
    • Hart DP, Avivi I, Thomson KJ, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Morris EC, Peggs KS, Mackinnon S (2003). Use of Positron Emission Tomography following reduced intensity allograft for Hodgkin and Non Hodgkin Lymphoma to guide Donor Lymphocyte Infusion administration..
    • Peggs KS, Thomson K, Chopra R, Mahendra P, Milligan D, Parker A, Hunter A, Pettengell R, Craddock CF, Hale G, Waldmann H, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2003). Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect..
    • D'Sa S, Kyriakou C, Bhattacharya S, Peggs K, Foulkes B, Ings S, Watts M, Ardeshna KM, Goldstone AH, Yong K, Williams C (2003). Etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) can cytoreduce resistant myeloma patients and mobilise them for transplant without adverse effects..
    • Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Madrigal JA, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI (2003). The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. BRIT J HAEMATOL, 123(5), 886 - 895.
    • Tauro S, Craddock C, Peggs K, Begum G, Chopra R, Littlewood T, Parker A, Marsh J, Cook G, Hale G, Snowden J, Milligan D, Hunter A, Russell N, Goldstone A, Mahendra P, Linch D, Mackinnon S (2003). Allogeneic stem cell transplantation using a campath-1H based reduced-intensity-conditioning regimen improves survival in adults with high risk acute myeloid leukaemia and myelodysplasia..
    • PREISER W, Brink NS, AYLIFFE U, PEGGS KS, MACKINNON S, Tedder RS, Garson JA (2003). Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma. Journal of Clinical Virology, 26(1), 49 - 59.

    2002

    • Peggs KS, Paneesha S, Kottaridis PD, Chakraverty RK, Tobias G, Reilly M, Mahendra P, Yong K (2002). Peripheral blood stem cell transplantation for POEMS syndrome.. Bone Marrow Transplant, 30(6), 401 - 404. doi:10.1038/sj.bmt.1703670
    • Kottaridis PD, Craddock C, Chopra R, Milligan DW, Vandenberghe E, Parker A, Hunter A, Schey S, Smith G, Hatton C, Hale G, Waldmann H, Peggs K, Avivi I, Linch DC, Goldstone AH, Mackinnon S (2002). Reduced intensity allogeneic transpalntation in patients above the age of 50 years..
    • Peggs KS, Mackinnon S, Yong K (2002). Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma.. J Clin Oncol, 20(20), 4268 - .
    • Tedder RS, Ayliffe U, Preiser W, Brink NS, Grant PR, Peggs KS, Mackinnon S, Kreig-Schneider F, Kirk S, Garson JA (2002). Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell-free cytomegalovirus. Journal of Medical Virology, 66(4), 518 - 523. doi:10.1002/jmv.2175
    • Verfuerth S, Pizzey AR, Geary J, Thomas AC, Peggs KS, Mackinnon S (2002). Magnetic sorting of gamma-IFN-producing T lymphocytes following in vitro restimulations by CMV antigen-pulsed dendritic cells results in a much more diverse range of CMV-specific T cells than CMV-pp65-HLA tetramer selection..
    • Peggs KS, Morris EC, Kottaridis PD, Geary J, Goldstone AH, Linch DC, Mackinnon S (2002). Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen.. Blood, 99(12), 4642 - 4643.
    • Peggs KS, Thomson K, Geary J, Morris E, Kottaridis P, Watts M, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002). Dose escalating donor lymphocyte infusions (DLI) following T-depleted reduced intensity allografting: High response rates associated with conversion to full donor chimerism (FDC) are not durable despite persistent donor chimerism..
    • Peggs KS, Mackinnon S (2002). Adoptive cellular therapy: a therapeutic reality?. Hematology, 7(3), 127 - 136. doi:10.1080/1024533021000013915
    • Kottaridis PD, Peggs K, Schmitz N, Dreger P, Boogaerts MA, Ferrant A, Demuynck HM, Zander A, Link H, Matcham J, Linch DC, Borkett K, Goldstone AH (2002). Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftment.. Leukemia and Lymphoma, 43(3), 531 - 536.
    • Peggs KS, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S (2002). Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells.. Blood, 99(1), 213 - 223.
    • Chakraverty R, Peggs K, Chopra R, Milligan D, Kottaridis P, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams C, Yong K, Linch DC, Goldstone A, Mackinnon S (2002). Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.. Blood, 99(3), 1071 - 1078.
    • Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S (2002). Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells.. Blood, 99(1), 213 - 223.
    • Peggs KS, Mackinnon S (2002). Clinical trials with CMV-specific T cells.. Cytotherapy, 4(1), 21 - 28. doi:10.1080/146532402317251491
    • Rew SB, Lopes L, Peggs K, Koishihara Y, Kosaka M, Ozaki S, Chain B, Yong KL (2002). Generation of T-cell mediated immune responses to the myeloma antigen, HM1.24..
    • Morris E, Thomson K, Craddock C, Milligan D, Smith GM, Parker A, Schey S, Winfield D, Chopra R, Littlewood T, Tighe J, Hunter A, Kyriakou C, Kottaridis P, Peggs K, Linch D, Goldstone A, Mackinnon S (2002). Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL)..
    • Geary JE, Verfuerth S, Thomas AC, Peggs KS, Mackinnon S (2002). Kinetics of lineage-specific chimerism following an alemtuzumab (Campath-1H) reduced intensity regimen and the effect on chimerism of donor leukocyte infusions..
    • Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW (2002). High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.. Blood, 99(12), 4357 - 4363.
    • Peggs K (2002). Donor lymphocyte infusion following reduced intensity allografting.

    2001

    • D'Sa SP, Peggs KS, Thuraisundaram D, Fox R, Goldstone AH, Mackinnon S, Yong KL (2001). CAMPATH-1H-containing nonmyeloablative allogeneic stem cell transplantation for myeloma results in delayed T cell reconstitution and a high incidence of viral infections, but low infection-related mortality..
    • Peggs KS, Mackinnon S (2001). Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation.. Br J Haematol, 115(4), 1032 - 1033.
    • Peggs KS, Mackinnon S (2001). Exploiting graft-versus-tumour responses using donor leukocyte infusions.. Best Pract Res Clin Haematol, 14(4), 723 - 739. doi:10.1053/beha.2001.0169
    • Kyriakou CA, Milligan D, Chopra R, Craddock C, Chakraverty R, Mahendra P, Pettengell R, Hunter A, Parker A, Vanderberghe E, Hatton C, Schey S, Kottaridis PD, Peggs K, Morris E, Hale G, Waldmann H, Linch DC, Goldstone AH, Mackinnon S (2001). Outcome of non-myeloablative stem cell transplantation for NHL is dependent on histology: Good for patients with low grade disease and poor for those with high grade lymphoma..
    • Kottaridis PD, Milligan DW, Chopra R, Craddock C, Kyriacou C, Peggs K, Cakrabati S, Geary J, Thuraisundaram D, Mahendra P, Chakraverty R, Hunter A, Pettengell R, Hale G, Waldmann H, Linch DC, Goldstone AH, Mackinnon S (2001). Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect..
    • Peggs K, Craddock C, Milligan D, Chopra R, Mahendra P, Chakraverty R, Hunter A, Parker A, Pettengell R, Vandenberghe E, Hale G, Waldmann H, Kottaridis P, Morris E, Goldstone A, Linch D, Mackinnon S (2001). Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia..
    • Peggs K, D'Sa S, Kyriacou C, Thuraisundaram D, Williams C, Goldstone A, Mackinnon S, Yong K (2001). Non-myeloablative allogeneic transplantation as front-line treatment for multiple myeloma: Response rates to conditioning and subsequent donor lymphocyte infusions..
    • Morris E, Rebello P, Thomson K, Peggs K, Kyriakou C, Goldstone A, Linch D, Mackinnon S, Hale G (2001). Pharmacokinetics of Campath-1H in vivo T cell depletion in non-myeloablative allogeneic transplants: Relevance for early adoptive immunotherapy..
    • Peggs K, Kottaridis P, Morris E, Kyriacou C, Geary J, Yong K, Goldstone A, Linch D, Mackinnon S (2001). Escalating dose donor lymphocyte infusions following non-myeloablative allogeneic transplantation are associated with minimal toxicity with sibling donors but a significant risk of severe GVHD with unrelated donors..
    • Peggs K, Verfuerth S, Pizzey A, Khan N, Moss P, Mackinnon S (2001). Cytomegalovirus-specific adoptive cellular therapy results in massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation following allogeneic transplantation..
    • Peggs K, Verfuerth S, Mackinnon S (2001). Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions.. Blood, 97(4), 994 - 1000.
    • Chakraverty R, Rabin N, Peggs K, Robinson S, Duncan JR, Yong K (2001). Dermatomyositis and sarcoid-like reaction associated with multiple myeloma treated effectively by high-dose chemotherapy and autologous peripheral blood stem cell transplantation.. Bone Marrow Transplantation, 27(11), 1215 - 1217.
    • Peggs KS, Mackinnon S (2001). Cellular therapy: donor lymphocyte infusion.. Curr Opin Hematol, 8(6), 349 - 354.
    • Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S (2001). In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.. Cytotherapy, 3(3), 197 - 201. doi:10.1080/146532401753174025
    • Chakrabarti S, Mackinnon S, Kottaridis P, Hale G, Osman H, Peggs K, Fegan C, Linch D, Milligan D (2001). Community respiratory virus and adenovirus infections in nonmyeloablative transplant recipients conditioned with. Campath-1H: High incidence but low mortality..
    • Chakraverty R, Robinson S, Peggs K, Kottaridis PD, Watts MJ, Ings SJ, Hale G, Waldmann H, Linch DC, Goldstone AH, Mackinnon S (2001). Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.. Bone Marrow Transplant, 28(9), 827 - 834. doi:10.1038/sj.bmt.1703248

    2000

    • Peggs KS, Mahendra P, Milligan DW, Chopra R, Chakraverty RK, Kottaridis PD, Chakrabarti S, Mills AK, Parker A, Hunter AE, Hale G, Waldmann H, Pettengell R, Marsh JCW, Schey S, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S, UK Collaborative Grp (2000). Non-myeloablative transplantation using matched unrelated donors - In vivo CAMPATH-1H limits graft versus host disease..
    • Verfuerth S, Peggs K, Mackinnon S (2000). A versatile culture system for the in vitro expansion of autologous donor-derived cytomegalovirus, Epstein Barr virus and Aspergillus antigen-specific T cells..
    • Chakrabarti S, Kottaridis P, Ogormon P, Peggs K, Osman H, Chopra R, Mackinnon S, Milligan DW (2000). High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (anti-CD52 antibody)..
    • Peggs KS, Verfuerth S, Khan N, Moss PAH, Mackinnon S (2000). Massive in vivo expansion of CMV-specific T-cells following adoptive transfer post allogeneic transplantation: Quantitation using HLA-peptide tetramers and T-cell receptor (TCR) spectratyping..
    • Peggs KS, Williams CD, Chopra R, D'Sa S, Thuraisundaram D, Schey S, Craddock C, Parker A, Goldstone AH, Mackinnon S, Yong K, UK Collaborative Study (2000). Non-myeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma.. BLOOD, 96(11), 781A - 781A.
    • Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000). In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.. Blood, 96(7), 2419 - 2425.
    • Kottaridis PD, Peggs K, Devereux S, Goldstone AH, Mackinnon S (2000). Simultaneous occurrence of Clostridium difficile and Cytomegalovirus colitis in a recipient of autologous stem cell transplantation. HAEMATOLOGICA, 85(10), 1116 - 1117.
    • Verfuerth S, Peggs K, Vyas P, Barnett L, O'Reilly RJ, Mackinnon S (2000). Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire.. Blood, 95(12), 3990 - 3995.
    • Kottaridis PD, Milligan DW, Mahendra P, Chopra R, Chakraverty R, Chakrabarti S, Peggs K, Robinson S, Verfuerth S, Parker A, Hunter DE, Pettengell R, Marsh JCW, Shey S, Morgan GJ, Williams CD, Hale G, Waldmann H, Yong K, Devereux S, Linch DC, Goldstone AH, Mackinnon S, UK Collaborative Study (2000). Non-myeloablative conditioning limits transplant related mortality in patients who have previously failed high dose treatment..
    • Mills AK, Goldstone AH, Linch DC, Peggs KS, Kyriakou C, Mackinnon S (2000). Long-term follow-up of allogeneic bone marrow transplants for lymphoma: The case for conventional conditioning regimens..
    • Chakraverty R, Robinson S, Peggs K, Kottaridis P, Watts M, Ings S, Hale G, Waldmann H, Linch D, Goldstone A, Mackinnon S (2000). Excessive T-cell depletion adversely affects transplant-related mortality following allogeneic stem cell transplantation..
    • Kottaridis PD, Peggs K, Lawrence A, Verfuerth S, Chatterjee R, Telfer P, Porter JB, Mackinnon S, Goldstone AH (2000). One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of bothmarrow disorders.. Bone Marrow Transplantation, 25, 677 - 678.
    • Peggs KS, Ings SJ, Kottaridis PD, Yong K, Williams CD, Goldstone AH, Mackinon S (2000). Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring.. Blood, 96(1), 369 - 370.
    • Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, Goldstone AH, Linch DC, Mackinnon S (2000). Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.. Br J Haematol, 111(3), 782 - 790.

    1999

    • Peggs KS, Kottaridis PD, Preiser W, McCaig N, Brink N, Ward K, Tedder R, Goldstone AH, Linch DC, Mackinnon S (1999). Molecular monitoring for CMV infection after allogeneic transplantation: Benefits and limitations of PCR directed pre-emptive antiviral therapy..
    • Kottaridis PD, Peggs K, Harrison C, Angus G, Peniket A, Miller B, Devereux S, Mackinnon S, Linch DC, Goldstone AH (1999). Age over 60 is not a barrier for successful autologous stem cell transplantation in selected patients with lymphoma: A single institution's experience in 37 consecutive patients..
    • Verfuerth S, Peggs KS, Vyas P, Barnett L, O'Reilly RJ, Mackinnon S (1999). Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping following T cell depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T cell repertoire..
    • Peggs KS, Verfuerth S, Ainsworth J, Pizzey A, Moss PAH, Mackinnon S (1999). CMV specific HLA-tetramer sorting of ex-vivo expanded CD8+CTL: Selection of highly restricted clonal populations suitable for adoptive cellular therapy..
    • Verfuerth S, Peggs K, Mackinnon S (1999). Generation of CMV-specific T cells for adoptive immunotherapy after allogeneic BMT: A novel in vitro culture assay that is free of live virus which uses donor dendritic cells pulsed with CMV antigen..
    • Yung L, Kottaridis PD, Peggs K, Miller B, McKeag N, Devereux S, Goldstone AH, Linch D, Mackinnon S (1999). Older age is not a barrier to successful allogeneic BMT..
    • Kottaridis PD, Ketley N, Peggs K, Chakraverty R, Ralleigh G, Shaw P, Pezzella F, Goldstone AH, Devereux S, Mackinnon S (1999). An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogenic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion. Bone Marrow Transplantation, 24(7), 807 - 809.

    1998

    • Peggs K, Kottaridis P, Goldstone AH, Littlewood T, Mackinnon S (1998). Impaired T cell reconstitution following high dose therapy supported with CD34+ selected or unselected peripheral blood stem cells in patients with multiple myeloma..

    1996

    • Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ (1996). The incidence and cause of coagulopathies in an intensive care population.. Br J Haematol, 93(2), 460 - 463.